Join Growin Stock Community!

Bicara therapeutics inc. common stockBCAX.US Overview

US StockHealthcare
(No presentation for BCAX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCAX AI Insights

BCAX Overall Performance

BCAX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCAX Recent Performance

-1.07%

Bicara therapeutics inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

BCAX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCAX Key Information

BCAX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCAX Profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Price of BCAX

BCAX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCAX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.22
PE Ratio (TTM)
3.12
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.28
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.22
PE Ratio (TTM)
3.12
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.28
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is BCAX's latest earnings report released?

    The most recent financial report for Bicara therapeutics inc. common stock (BCAX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCAX's short-term business performance and financial health. For the latest updates on BCAX's earnings releases, visit this page regularly.

  • How much debt does BCAX have?

    As of the end of the reporting period, Bicara therapeutics inc. common stock (BCAX) had total debt of 1.98M, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BCAX have?

    At the end of the period, Bicara therapeutics inc. common stock (BCAX) held Total Cash and Cash Equivalents of 171.67M, accounting for 0.4 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BCAX's EPS continuing to grow?

    According to the past four quarterly reports, Bicara therapeutics inc. common stock (BCAX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.67. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCAX?

    Bicara therapeutics inc. common stock (BCAX)'s Free Cash Flow (FCF) for the period is -29.29M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 69.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.